Lannett Inc (LCINQ) Gross Profit Margin starting from the third quarter 2023 to third quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Lannett Company Inc  (NONE: LCINQ)


Lannett Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LCINQ Gross Profit Margin (Mar 31 2023)
Q3 		(Dec 31 2022)
Q2 		(Sep 30 2022)
Q1 		(Jun 30 2022)
Q4 		(Mar 31 2022)
Q3
Y / Y Revenue Change 1.41 %
Seq. Revenue Change 9.29 %
Revenue In Millions $79.46
Gross Profit Margin 19.1 %
Gross Profit Margin Total Ranking # 3322
Gross Profit In Millions $15.18
Y / Y Gross Profit Change 393.01 %
Seq. Gross Profit Change 6.28 %


Commenting Third Quarter 2023 Gross Profit Margin
Lannett Inc has managed to improve its Revenue sequentially to $79.46 millions by 9.29 % faster than Gross Profit increase of 6.28 % to $15.18 millions, this led to contraction in Gross Profit Margin to 19.1 %, below company average.


Observing third quarter 2023 results within Major Pharmaceutical Preparations industry 164 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 3322, from total ranking in the previous quarter at 3360.
Learn about Gross Margin
LCINQ's Gross Profit Margin third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 496
Overall # 3265

Gross Profit Margin Statistics
High Average Low
89.54 % 47.27 % 0.58 %
(Dec 31 2018)   (Dec 31 2020)


LCINQ Gross Income Trends • More of LCINQ's Profitabilty Ratios • LCINQ Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
LCINQ's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
LCINQ's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for LCINQ's Competitors
Gross Profit Margin Profit Margin for Lannett Inc's Suppliers
Gross Profit Margin Profit Margin for LCINQ's Customers

You may also want to know
LCINQ's Annual Growth Rates LCINQ's Profitability Ratios LCINQ's Asset Turnover Ratio LCINQ's Dividend Growth
LCINQ's Roe LCINQ's Valuation Ratios LCINQ's Financial Strength Ratios LCINQ's Gross Profit Growth
LCINQ's Roa LCINQ's Inventory Turnover Ratio LCINQ's Growth Rates LCINQ's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2023 MRQ Gross ProfitMar 31 2023 MRQ Revenue
Opko Health Inc   51.99 %$ 123.518  Millions$ 237.577  Millions
Akebia Therapeutics Inc   51.44 %$ 20.643  Millions$ 40.127  Millions
Vireo Growth Inc.  49.87 %$ 9.520  Millions$ 19.088  Millions
Fortress Biotech Inc   48.11 %$ 5.980  Millions$ 12.429  Millions
Impel Pharmaceuticals Inc   47.74 %$ 2.087  Millions$ 4.372  Millions
Agile Therapeutics Inc  47.47 %$ 1.810  Millions$ 3.813  Millions
Journey Medical Corp  47.20 %$ 5.764  Millions$ 12.213  Millions
Taro Pharmaceutical Industries Ltd  46.83 %$ 268.323  Millions$ 572.952  Millions
Lftd Partners Inc   45.33 %$ 5.648  Millions$ 12.462  Millions
American Bio Medica Corporation  45.12 %$ 0.074  Millions$ 0.164  Millions
Earth Science Tech Inc   44.24 %$ 0.020  Millions$ 0.046  Millions
23andme Holding Co  43.28 %$ 39.982  Millions$ 92.377  Millions
Teva Pharmaceutical Industries Limited  43.21 %$ 1,582.000  Millions$ 3,661.000  Millions
Cryoport inc   43.10 %$ 27.072  Millions$ 62.817  Millions
Heron Therapeutics Inc   43.09 %$ 12.761  Millions$ 29.615  Millions
Cv Sciences Inc   42.96 %$ 1.782  Millions$ 4.148  Millions
Nabriva Therapeutics Plc  41.53 %$ 3.152  Millions$ 7.590  Millions
Viatris Inc   41.36 %$ 1,542.200  Millions$ 3,729.100  Millions
Elite Pharmaceuticals Inc   39.82 %$ 3.441  Millions$ 8.642  Millions
Igc Pharma Inc   38.18 %$ 0.063  Millions$ 0.165  Millions
Sunshine Biopharma Inc   37.35 %$ 1.828  Millions$ 4.894  Millions
Camp4 Therapeutics Corporation  35.33 %$ 27.738  Millions$ 78.506  Millions
Perrigo Company Plc  35.04 %$ 413.800  Millions$ 1,180.800  Millions
Amneal Pharmaceuticals Inc   31.98 %$ 178.186  Millions$ 557.186  Millions
Phibro Animal Health Corporation  30.75 %$ 75.540  Millions$ 245.673  Millions
Hcw Biologics Inc   29.92 %$ 0.013  Millions$ 0.042  Millions
Gelesis Holdings Inc   29.44 %$ 0.516  Millions$ 1.753  Millions
Longeveron Inc   27.24 %$ 0.076  Millions$ 0.279  Millions
Lifecore Biomedical Inc   22.16 %$ 5.978  Millions$ 26.978  Millions
Avid Bioservices Inc   21.51 %$ 8.391  Millions$ 39.013  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.